CoChat
Sign Up
Cited by 127

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

Sieper, Joachim, Braun, Jürgen, Kay, Jonathan, Badalamenti, Salvatore, Radin, Allen R, Jiao, Lixia, Fiore, Stefano, Momtahen, Tanya, Yancopoulos, George D, Stahl, Neil, Inman, Robert D·2015·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2013-204963PMC PMC4431338
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2013-204963

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition. SC, subcutaneous; q2w, every 2 weeks; qw, every week.
Figure 1 Patient disposition. SC, subcutaneous; q2w, every 2 weeks; qw, every week.CC BY-NC · PubMed Central
Figure 2 Incidence of ASAS20 response – ITT population. Percentage response calculated using the number of ITT patients in the corresponding treatment group within each subgroup as denominator. At week 12, p>0.05 (nominal and adjusted) for all sarilumab-treated groups vs placebo. CRP, high sensitivity C-reactive protein; ITT, intent-to-treat.
Figure 2 Incidence of ASAS20 response – ITT population. Percentage response calculated using the number of ITT patients in the corresponding treatment group within each subgroup as denominator. At week 12, p>0.05 (nominal and adjusted) for all sarilumab-treated groups vs placebo. CRP, high sensitivity C-reactive protein; ITT, intent-to-treat.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 28

  1. Braun, 1998, Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors, Arthritis Rheum, 41, 58, 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G · DOI
  2. Sieper, 2006, Concepts and epidemiology of spondyloarthritis, Best Pract Res Clin Rheumatol, 20, 401, 10.1016/j.berh.2006.02.001 · DOI
  3. Zink, 2000, Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers, J Rheumatol, 27, 613
  4. Reveille, 1998, HLA-B27 and the seronegative spondyloarthropathies, Am J Med Sci, 316, 239, 10.1016/S0002-9629(15)40414-8 · DOI
  5. Braun, 2007, Ankylosing spondylitis, Lancet, 369, 1379, 10.1016/S0140-6736(07)60635-7 · DOI
  6. Mansour, 2007, Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment, Semin Arthritis Rheum, 36, 210, 10.1016/j.semarthrit.2006.08.003 · DOI
  7. Braun, 2008, Editorial: What is the most important outcome parameter in ankylosing spondylitis, Rheumatology, 47, 1738, 10.1093/rheumatology/ken357 · DOI
  8. Haberhauer, 2010, Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis vs. rheumatoid arthritis, Wien Med Wochenschr, 160, 220, 10.1007/s10354-010-0795-0 · DOI
  9. Rajalingham, 2012, Antagonizing IL-6 in ankylosing spondylitis: a short review, Inflamm Allergy Drug Targets, 11, 262, 10.2174/187152812800958979 · DOI
  10. Smolen, 2007, New therapies for treatment of rheumatoid arthritis, Lancet, 370, 1861, 10.1016/S0140-6736(07)60784-3 · DOI
  11. Braun, 1995, Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis, Arthritis Rheum, 38, 499, 10.1002/art.1780380407 · DOI
  12. Bal, 2007, Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis, Clin Rheumatol, 26, 211, 10.1007/s10067-006-0283-5 · DOI
  13. Visvanathan, 2008, Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab, Ann Rheum Dis, 67, 511, 10.1136/ard.2007.071605 · DOI
  14. Pedersen, 2011, Arthritis Rheum, 63, 3789, 10.1002/art.30627 · DOI
  15. Henes, 2010, Mixed response to tocilizumab for ankylosing spondylitis, Ann Rheum Dis, 69, 2217, 10.1136/ard.2009.126706 · DOI
  16. Brulhart, 2010, Tocilizumab in a patient with ankylosing spondylitis and Crohn’s disease refractory to TNF antagonists, Joint Bone Spine, 77, 625, 10.1016/j.jbspin.2010.08.004 · DOI
  17. Cohen, 2011, Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab, J Rheumatol, 38, 1527, 10.3899/jrheum.110265 · DOI
  18. Shima, 2011, Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis, Mod Rheumatol, 21, 436, 10.3109/s10165-011-0416-9 · DOI
  19. Sieper, 2014, Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials, Ann Rheum Dis, 73, 95, 10.1136/annrheumdis-2013-203559 · DOI · Paper page
  20. Garrett, 1994, A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol, 21, 2286
  21. Anderson, 2001, Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis, Arthritis Rheum, 44, 1876, 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F · DOI
  22. Calin, 1994, A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index, J Rheumatol, 21, 2281
  23. Braun, 2003, Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system, Arthritis Rheum, 48, 1126, 10.1002/art.10883 · DOI
  24. Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 · DOI
  25. Huizinga, 2014, Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial, Ann Rheum Dis, 73, 1626, 10.1136/annrheumdis-2013-204405 · DOI
  26. Kiltz, 2012, Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?, Curr Opin Rheumatol, 24, 252, 10.1097/BOR.0b013e3283524b82 · DOI
  27. Busquets-Perez, 2013, Emerging drugs for axial spondyloarthritis including ankylosing spondylitis, Expert Opin Emerging Drugs, 18, 71, 10.1517/14728214.2013.752815 · DOI
  28. Baeten, 2013, Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind placebo-controlled trial, Lancet, 382, 1705, 10.1016/S0140-6736(13)61134-4 · DOI

Cited by

Sorted by citations

Metadata

Authors
Sieper, J., Braun, J., Kay, J., Badalamenti, S., Radin, A. R., Jiao, L., Fiore, S., Momtahen, T., Yancopoulos, G. D., Stahl, N., & Inman, R. D.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-06
Volume
74
Issue
6
Pages
1051-1057
ISSN
0003-4967
DOI
10.1136/annrheumdis-2013-204963
PMC
PMC4431338
Cited by
127
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review